During the past decade, Texas Retina Associates conducted 35 clinical trials. In the 10-year time frame, 35 clinical trials started and 19 clinical trials were completed, i.e. on average, 54.3% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 14 clinical trials were completed. i.e. 82.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Retina Associates" #1 sponsor was "Hoffmann-La Roche" with 11 trials, followed by "Jaeb Center for Health Research" with 7 trials sponsored, "Clearside Biomedical, Inc." with 6 trials sponsored, "National Eye Institute (NEI)" with 5 trials sponsored and "Aura Biosciences" with 5 trials sponsored. Other sponsors include 22 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Retina Associates" #1 collaborator was "National Eye Institute (NEI)" with 10 trials as a collaborator, "Genentech, Inc." with 4 trials as a collaborator, "Allergan" with 3 trials as a collaborator, "Chugai Pharmaceutical" with 2 trials as a collaborator and "The Emmes Company, LLC" with 2 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Texas Retina Associates" are "Diabetic Macular Edema" (11 trials), "Geographic Atrophy" (7 trials), "Diabetic Retinopathy" (6 trials), "Panuveitis" (5 trials) and "Uveitis, Intermediate" (5 trials). Many other conditions were trialed in "Texas Retina Associates" in a lesser frequency.

Most popular intervention types in "Texas Retina Associates" are "Drug" (47 trials), "Procedure" (11 trials), "Other" (9 trials), "Device" (2 trials) and "Diagnostic Test" (2 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (8 trials), "Faricimab" (6 trials), "Aflibercept" (5 trials), "Lampalizumab" (4 trials) and "Placebo" (3 trials). Other intervention names were less common.

The vast majority of trials in "Texas Retina Associates" are 59 trials for "All" genders.

Currently, there are NaN active trials in "Texas Retina Associates". undefined are not yet recruiting, 5 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 34 completed trials in Texas Retina Associates, 1 suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Retina Associates, 1 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 33 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".